Nexsen has locked in over $1.5 million in non-dilutive funding through a national research partnership, accelerating manufacturing scale-up and platform optimisation for its rapid diagnostics technology.
- Over $1.5 million non-dilutive funding secured
- Partnership with ARC’s SAGE-Manufacturing centre
- Focus on catalysis science to enhance diagnostic sensitivity
- Two full-time researchers embedded in Nexsen’s R&D
- Leverage of eight times annual cash investment
National Research Partnership Fuels Nexsen’s Manufacturing Ambitions
Nexsen Limited (ASX:NXN) has secured more than $1.5 million in non-dilutive funding through its admission as an industry partner to the Australian Research Council’s SAGE-Manufacturing centre. This five-year collaboration with leading institutions including Monash University, RMIT, Deakin University, and CSIRO aims to accelerate manufacturing scale-up and platform optimisation for Nexsen’s rapid diagnostics technology.
The funding arrangement requires Nexsen to contribute just $35,000 in cash annually, plus an equivalent in-kind commitment, delivering more than eight times leverage on its investment. This capital-efficient support aligns with Nexsen’s 2026 priority to expand its R&D capacity and manufacturing readiness ahead of future commercialisation.
Catalysis Science to Enhance Diagnostic Performance
At the heart of the partnership is the application of advanced catalysis science to Nexsen’s proprietary rapid diagnostics platform. The project focuses on catalytic signal enhancement and scalable device manufacturing, targeting improvements in detection sensitivity, reliability, and performance consistency across Nexsen’s test pipeline.
Two full-time researchers from the SAGE-Manufacturing centre will be embedded at Nexsen’s Australian R&D facility to work alongside the company’s scientific team. This hands-on collaboration is expected to fast-track manufacturing optimisation and platform refinement, critical steps in Nexsen’s strategy to build scalable production capability for its diagnostics.
Strategic Fit within Nexsen’s Growth Trajectory
Nexsen’s rapid diagnostics suite addresses significant unmet clinical needs, including its lead GBS Rapid Sensor for Group B Streptococcus detection and kidney function tests targeting Acute Kidney Injury and Chronic Kidney Disease. The company’s broader ambition is to become a global leader in rapid point-of-care diagnostics, delivering lab-grade results swiftly to improve patient outcomes.
This latest partnership complements Nexsen’s ongoing efforts to advance regulatory readiness and clinical validation, following recent progress such as its strategic collaboration with GHK Hospital in Hong Kong to validate diagnostics in North Asia. By securing non-dilutive funding that enhances manufacturing capabilities without shareholder dilution, Nexsen is positioning itself to meet future demand with greater capital efficiency.
Bottom Line?
Nexsen’s collaboration with SAGE-Manufacturing offers a rare blend of scientific expertise and funding efficiency, but the impact on commercial timelines and product rollout remains to be demonstrated.
Questions in the middle?
- How will advances in catalysis science translate into measurable improvements in Nexsen’s diagnostic accuracy and reliability?
- What milestones will Nexsen set to assess progress from embedded researchers and manufacturing scale-up?
- Could this partnership open doors to further government or industry funding to support Nexsen’s commercial ambitions?